Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8229079 | 0.81 | AAK1 (0.42) | ABCB1ABCC1AAK1HDAC1HDAC2 | |
| SCHEMBL4580218 | 0.79 | ABCC1 (0.44) | ABCB1ABCC1MAPTMAPK1 | |
| SCHEMBL13737286 | 0.76 | HDAC2 (0.60) | HDAC1HDAC2HDAC3 | |
| SCHEMBL651882 | 0.73 | HDAC1 (0.57) | ABCB1ABCC1HDAC1HDAC2HDAC3 | |
| SCHEMBL13735115 | 0.71 | HDAC1 (0.55) | ABCB1ABCC1HDAC1HDAC2HDAC3 | |
| SCHEMBL7467565 | 0.70 | AAK1 (0.61) | ABCB1ABCC1AAK1HDAC1HDAC2 | |
| SCHEMBL7466561 | 0.70 | GSK3B (0.39) | ABCB1ABCC1AAK1HDAC1HDAC2 | |
| SCHEMBL20163155 | 0.68 | HDAC2 (0.58) | ABCB1ABCC1HDAC1HDAC2HDAC3 | |
| SCHEMBL975555 | 0.68 | KCNH2 (0.56) | ABCB1AAK1HDAC1MAPT | |
| SCHEMBL13735378 | 0.68 | HDAC1 (0.52) | ABCB1ABCC1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | ABCB1 4043/4885ABCC1 3326/4885AAK1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.